Publication: Tip 2 Diabetik Koroner Arter hastalığı olan bireylerde Trombin-Antitrombin (TAT) kompleksinin takibi
Abstract
Günümüzde aterosklerozun neden olduğu koroner arter hastalığı (KAH) en önemli ölüm nedenlerinden biridir. Diabet ise koroner arter hastalığına yaptığı katkı ile gündemdedir. Bu çalışma, diabete bağlı koroner arter hastalığı ile antikoagülasyon faktörü antitrombin III (AT-III) ve ox LDL düzeyleri arasındaki ilişkiyi araştırmak için planlandı. 10 sağlıklı kontrolün (Grup 1) ve Marmara Üniversitesi Hastanesi Kalp Damar Cerrahisi Anabilim dalında takip edilmekte olan 19 Tip 2 Diabetik koroner arterli hastanın (Grup 2) plazmalarında CRP ve Fibrinojen düzeyleri belirlendi. CRP ve fibrinojen düzeyleri hasta plazmalarında kontrollere göre anlamlı derecede yüksek bulundu (p=0.001). HbA1c düzeyleri ve diyabetin süresi açısından her grup arasında anlamlı fark görüldü (p<0.001). Trombosit sayısı değerlendirildiğinde gruplar arasında anlamlı bir fark bulunmadı (p>0.05). Hasta grubu ve kontrollerin plazma LDL kolesterol düzeyleri anlamlı derecede farklı bulundu (p<0.001). ELISA yöntemi ile trombin-antitrombin kompleksinin (TAT) ve okside-düşük yoğunluklu lipoprotein (ox-LDL) miktarı tayin edildi. Analiz sonucunda kontrollere karşı (Grup 1; 29,27±24.14 ng/ mL) hasta plazmalarındaki (Grup 2; 10.12±3.62 ng/ mL) TAT kompleksi düzeyleri arasında anlamlı bir fark bulundu (p<0.001). Kontrol (Grup 1; 123.26±17.18 pg/ mL) ve hasta plazmalarının (Grup 2; 122.87±27.13 pg/ mL) ox-LDL değerleri arasında ise anlamlı bir fark bulunmadı (p>0.05) koagulasyon anormallikleri, tip 2 diabet, koroner arter hastalığı, trombin- antitrombin kompleksi
Evaluation of Thrombin-Antithrombin complex in patients with type 2 diabetic coronary artery disease. Nowadays, Coronary artery disease (CAD) caused by atherosclerosis is one of the major causes of the death. This study was planned to investigate the relationship between atheroschlerosis and anticoagulation factor antithrombin III (AT-III) and oxide LDL levels in the diabetic coroneray artery diseases. In this study, to evaluate the role of the coagulation abnormalities, TAT complex levels were evaluated in diabetic coronary artery diseases (Group 2). TAT complex levels in the plasma of 10 control grup (Group 1) and 19 patients (Group 2) were assessed by ELISA method. C-reactif protein (CRP) and fibrinogen levels were assed in plasma of 19 patient and 10 control groups in Marmara University Cardiovascular medicine department. CRP and fibrinogen levels in patient plasmas were found high in significant level (p=0.001). HbA1c (p<0.001) levels and in terms of diabetes duration in both group were observed meaningful difference (p<0.001). A significant difference was not detected between groups in terms of platelet levels (p>0.05). A significant difference has been detected between plasma LDL levels of patient and control groups (p<0.001). By using ELISA method, TAT and ox-LDL levels were assesed. At the end of the assesment, we observed that levels of TAT complex in the plasma collected from control (Group 1; 29,27±24.14 ng/ mL ) and patients (Group 2; 10.12±3.62 ng/ mL) were different significantly (p<0.001). In addition to this, a significant difference has not been detected between the oxidized LDL values of conrol (Group 1; 123.26±17.18 pg/ mL) and patient plasma (Group 2; 122.87±27.13 pg/ mL) (p>0.05). Key words: coagulation abnormalities, type 2 diabet, coronary artery disease, thrombin-antithrombin complex
Evaluation of Thrombin-Antithrombin complex in patients with type 2 diabetic coronary artery disease. Nowadays, Coronary artery disease (CAD) caused by atherosclerosis is one of the major causes of the death. This study was planned to investigate the relationship between atheroschlerosis and anticoagulation factor antithrombin III (AT-III) and oxide LDL levels in the diabetic coroneray artery diseases. In this study, to evaluate the role of the coagulation abnormalities, TAT complex levels were evaluated in diabetic coronary artery diseases (Group 2). TAT complex levels in the plasma of 10 control grup (Group 1) and 19 patients (Group 2) were assessed by ELISA method. C-reactif protein (CRP) and fibrinogen levels were assed in plasma of 19 patient and 10 control groups in Marmara University Cardiovascular medicine department. CRP and fibrinogen levels in patient plasmas were found high in significant level (p=0.001). HbA1c (p<0.001) levels and in terms of diabetes duration in both group were observed meaningful difference (p<0.001). A significant difference was not detected between groups in terms of platelet levels (p>0.05). A significant difference has been detected between plasma LDL levels of patient and control groups (p<0.001). By using ELISA method, TAT and ox-LDL levels were assesed. At the end of the assesment, we observed that levels of TAT complex in the plasma collected from control (Group 1; 29,27±24.14 ng/ mL ) and patients (Group 2; 10.12±3.62 ng/ mL) were different significantly (p<0.001). In addition to this, a significant difference has not been detected between the oxidized LDL values of conrol (Group 1; 123.26±17.18 pg/ mL) and patient plasma (Group 2; 122.87±27.13 pg/ mL) (p>0.05). Key words: coagulation abnormalities, type 2 diabet, coronary artery disease, thrombin-antithrombin complex